Misplaced Pages

MolMed

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
You can help expand this article with text translated from the corresponding article in Italian. (January 2025) Click for important translation instructions.
  • Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Misplaced Pages.
  • Consider adding a topic to this template: there are already 941 articles in the main category, and specifying|topic= will aid in categorization.
  • Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
  • You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Italian Misplaced Pages article at ]; see its history for attribution.
  • You may also add the template {{Translated|it|MolMed}} to the talk page.
  • For more guidance, see Misplaced Pages:Translation.

MOLMED is a biotechnology company founded in 1996 in Milan. It originally operated as contract manufacturing organization and other services for companies developing gene therapy and cell therapy products. In 2000, the company changed its business model and started to develop products of its own.

In 2001, it signed an agreement with San Raffaele Hospital, that gave MolMed an option to license any gene therapy or cell therapy invention made at the hospital in the fields of cancer and HIV.

The company was listed on the Milan Stock Exchange in 2008.

In early 2015, MolMed partnered with GlaxoSmithKline related to GSK's acquisition of Strimvelis; MolMed had been involved in the early development of the product. In March 2020 Fininvest, the reference shareholder with 23.13%, announced its intention to participate in the total takeover bid of the Japanese Agc (Mitsubishi) at the price of 0.518 euros per share, with a 110% premium compared to the price recorded in the session of the previous day (0.24 euro). As of 2020, the company is known as AGC Biologics.

References

  1. "MolMed Company Overview". The San Raffaele Biomedical Science Park.
  2. Taylor, Nick Paul (April 16, 2015). "MolMed picks up CAR-T asset from hot Italian research institute". FierceBiotech.
  3. Taylor, Nick Paul (September 2, 2016). "GSK dials up value of MolMed gene therapy pact to support growing operation". FierceBiotech.
  4. "Molmed, Opa dei giapponesi di Agc. Per Berlusconi 30 milioni di plusvalenza". Affaritaliani.it (in Italian). Retrieved 2022-12-08.
  5. "Opa giapponese su Molmed, la biotech dei Berlusconi per la lotta ai tumori". la Repubblica (in Italian). 2020-03-17. Retrieved 2022-12-08.
  6. "MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition". AGC. 2020-10-27. Retrieved 2024-03-26.

External links

Categories:
MolMed Add topic